Yes, they both require a prescription
Some patients with type 2 diabetes may maintain a lower dose if weight loss isnt a primary goal, or those with obesity and type 2 diabetes may move up to the highest maintenance dose
What sets our GLP-1 weight loss shot apart is its remarkable effectiveness for weight loss, achieved at doses much higher than those typically prescribed for diabetes treatment
While Ozempic is approved in New Zealand for managing type 2 diabetes, Wegovy is specifically approved for weight management in people who are overweight or obese
The drugs prescribing information states that adults with a body mass index (BMI) of 30 or higher have obesity, while adults with a BMI of 27 or higher are considered overweight
It is widely investigated in metabolic and body-composition research involving: Fat oxidation Caloric expenditure Glucose regulation Appetite-related pathways Metabolic efficiency Energy-utilization signaling Unlike earlier single- or dual-pathway incretin compounds, Retatrutide is researched for its broader multi-receptor metabolic activity, with experimental models exploring its potential influence on: Lipid metabolism Visceral-fat pathways Energy balance Metabolic signaling pathways Observed side effects in research settings are most commonly gastrointestinal and may include: Nausea Reduced appetite Bloating Reflux Constipation Diarrhea Fatigue Temporary digestive discomfort Responses may vary depending on administration amount, escalation speed, protocol duration, and individual sensitivity
